Equities Analysts Set Expectations for NRIX Q2 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for shares of Nurix Therapeutics in a research report issued to clients and investors on Wednesday, June 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.72) for the quarter, up from their previous forecast of ($0.73). HC Wainwright currently has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.94) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($2.59) EPS.

Several other research firms have also recently commented on NRIX. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Needham & Company LLC boosted their target price on Nurix Therapeutics from $26.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday. BTIG Research boosted their target price on Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial increased their target price on Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday. Finally, Jefferies Financial Group increased their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.14.

Nurix Therapeutics Price Performance

Shares of NRIX stock opened at $16.98 on Friday. The company’s fifty day simple moving average is $16.39 and its two-hundred day simple moving average is $16.92. Nurix Therapeutics has a 1 year low of $8.19 and a 1 year high of $22.50. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -5.37 and a beta of 1.86.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The company had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 14,055 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at $624,027.20. This represents a 27.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 3,214 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $16.65, for a total value of $53,513.10. Following the transaction, the insider directly owned 120,399 shares of the company’s stock, valued at $2,004,643.35. The trade was a 2.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 19,657 shares of company stock worth $326,586 over the last ninety days. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC raised its position in Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after purchasing an additional 1,190 shares during the last quarter. Intesa Sanpaolo Wealth Management bought a new stake in Nurix Therapeutics during the 4th quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd bought a new stake in Nurix Therapeutics during the 4th quarter valued at approximately $33,000. KBC Group NV bought a new stake in Nurix Therapeutics during the 1st quarter valued at approximately $34,000. Finally, Wexford Capital LP bought a new stake in Nurix Therapeutics during the 3rd quarter valued at approximately $41,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.